Skip to content

Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®

Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05813054
Acronym
DermiAge
Enrollment
60
Registered
2023-04-14
Start date
2022-10-01
Completion date
2023-09-15
Last updated
2024-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Skin Aging

Brief summary

Oral supplement with an HA matrix ingredient composed of HA (60-75%), sulfated GAGs (≥10%), including DS and CS, and collagen (≥ 5%) to evaluate the hydration of the stratum corneum of facial skin in healthy women showing natural signs of age-related aging versus placebo

Detailed description

This study includes 60 healthy volunteers in which will be evaluated if the oral supplement with Dermial \[composed of HA (60-75%), sulfated GAGs (≥10%), including DS and CS, and collagen (≥ 5%)\] is able to obtain differences versus placebo in healthy women showing natural signs of age-related aging versus placebo . It is a single-center, double-blind, randomized, placebo-controlled clinical study with proportion 1:1 between treatments.

Interventions

DIETARY_SUPPLEMENTHA matrix ingredient

1 capsule/day

DIETARY_SUPPLEMENTPlacebo

1 capsule/day

Sponsors

Bioiberica
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
35 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. Healthy women between 35 and 65 years of age (inclusive), showing signs of physiological facial skin aging. 2. Women willing not to use any firming product, skin lightening, or any other topical or systemic medication known to affect skin aging or dyschromia during the study period. 3. Be informed of the nature of the study and give their IC in writing. 4. Women willing not to become pregnant during the course of the study, using contraceptive methods considered highly effective.

Exclusion criteria

1. Women with allergies to the ingredients in the investigational product. 2. Women who have used a dietary or nutricosmetic supplement containing HA, or who have undergone Botox or HA infiltrations, in the last 6 months prior to signing the IC. 3. Women who have undergone: * Superficial or medium-deep chemical peels or dermabrasion within the 6 weeks prior to signing the IC or inclusion document. * Deep facial chemical peel, non-ablative laser or fractional laser resurfacing in the 12 months prior to signing the IC or inclusion document. * Facial plastic surgery or a laser ablative procedure for photoaging in the 12 months prior to signing the IC or inclusion document. 4. Suspected uncontrolled disease, such as diabetes mellitus (DM), arterial hypertension (HT), hyperthyroidism or hypothyroidism, renal failure or liver failure. 5. Women who have received a PRP (Platelet Rich Plasma) injection as a treatment for aesthetic purposes, in the 3 months prior to inclusion by signing the IC. 6. Women who do not wish, for whatever reason, to take the supplements in the study. 7. Known pregnancy or lactation. 8. Presence of inflammatory skin disease such as psoriasis, atopic dermatitis, rosacea, acne or hidradenitis suppurativa. 9. Presence of active malignant pathologies or premalignant skin lesions such as actinic keratoses. 10. Psychiatric disorder that is not managed or any other circumstance or pathology that prevents the participant from understanding and/or complying with the study procedures.

Design outcomes

Primary

MeasureTime frameDescription
Skin MoistureDay 0, 12 weekThe changes in the hydration of the facial stratum corneum using the Corneometer® CM825 measuring device, range: 0-130 arbitrary units

Secondary

MeasureTime frameDescription
Skin elasticityDay 0, 6 week, 12 weekThe changes of skin elasticity by Cutometer ® Dual MPA 580 probe, range: 0-100%.
Skin hardnessDay 0, 6 week, 12 weekThe changes of Skin hardness by PCE-DDO 10 Durometer probe, range: 0-100 Shore O.
Skin BarrierDay 0, 6 week, 12 weekThe changes of skin barrier in terms of TEWL (Trans Epidermal Water Loss) by Tewameter® TM300 probe, range: 0-80 (g\*m-2\*h-1).
Skin pHDay 0, 6 week, 12 weekThe changes of skin pH by Skin-pH-Meter®PH905 probe, range: pH0 (acidic) - pH12 (alkaline).
Skin temperatureDay 0, 6 week, 12 weekThe changes of the skin temperature by Skin-Thermometer ST500 probe, range: 15°C-40°C.
Antioxidant capacity of the skinDay 0, 6 week, 12 weekThe total antioxidant capacity will be measured in microcoulombs, using conductive hydrogel strips designed for the direct measurement of antioxidant capacity using eBQC®, range: 0-20 microcoulombs.
Erythema and skin melanin indexDay 0, 6 week, 12 weekThe erythema and melanin index will be measured in arbitrary units using the Mexameter® MX18 probe, range: 50-600 arbitrary units .
Skin MoistureDay 0, 6 week, 12 weekEvaluate changes in the hydration of the facial stratum corneum from baseline to 6 and 12 week by Corneometer® CM825 measuring device, range: 0-130 arbitrary units
Skin frictionDay 0, 6 week, 12 weekThe changes of the skin friction by Frictiometer FR-700, range: 0-30 arbitrary units .
Skin radianceDay 0, 6 week, 12 weekThe changes of the skin radiance by Skin-Glossymeter GL 200 probe, range: 0-100 arbitrary units.
Facial Wrinkles and Fine lines of Crow's feetDay 0, 6 week, 12 weekAssessment of Reduction in Facial Wrinkles and Fine lines of Crow's feet area by VisioScan. It consists of a UV light camera and measures the skin surface profiles. (0-500 Rz)
Glogau Photodamage ScaleDay 0, 6 week, 12 weekThe change between the photodamage grade by dermatologist physical examination of treated area. The Glogau Photodamage Scale has a score from 1-4 (Type I: No wrinkles, Type II: Wrinkles in motion, Type III: Wrinkles at rest, Type IV: Only wrinkles), this scale represents a qualitative assessment to measure the severity of photodamage and wrinkles.
Satisfaction assessedDay 0, 12 weekLevel of satisfaction with the sensation of skin hydration, texture, luminosity and smoothness using a self-administered 5-point Likert scale of intensity ( 1\_Very dissatisfied; 2\_Dissatisfied; 3\_Neither satisfied nor dissatisfied; 4\_Satisfied; 5\_Very) satisfied
Safety assessmentDay 0 to 12 week (anytime)Adverse events
Skin stiffness/deformabilityDay 0, 6 week, 12 weekThe changes of the stiffness/deformability by Indentometer IDM 800 probe, range: 0.00-3.00 millimeters.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026